NasdaqCM - Nasdaq Real Time Price USD

Adial Pharmaceuticals, Inc. (ADIL)

5.05 +1.34 (+36.12%)

At close: October 28 at 4:00:00 PM EDT

4.86 -0.19 (-3.76%)

After hours: October 28 at 7:52:34 PM EDT

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

GlobeNewswire 13h ago

ADIL
+36.12%
^IXIC
Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer

GlobeNewswire 2d ago

ADIL
+36.12%
Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis

GlobeNewswire 12d ago

ADIL
+36.12%
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 28d ago

ADIL
+36.12%
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 2mo ago

ADIL
+36.12%
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing

GlobeNewswire 4mo ago

ADIL
+36.12%
ADIL Stock Eyes Best Day In Over 5 Years — Major Pipeline Overhaul And $64M Raise Fuel Rally

Stocktwits 4mo ago

ADIL
+36.12%
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

GlobeNewswire 4mo ago

ADIL
+36.12%
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update

GlobeNewswire 5mo ago

ADIL
+36.12%
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045

GlobeNewswire 5mo ago

ADIL
+36.12%
Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program

GlobeNewswire 5mo ago

ADIL
+36.12%
Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial

GlobeNewswire 6mo ago

ADIL
+36.12%

Performance Overview

Return	ADIL	S&P 500 (^GSPC)
YTD	-8.18%	+13.13%
1-Year	-46.84%	+12.38%
3-Year	-90.05%	+88.08%

U.S. markets open in 4h 24m

Adial Pharmaceuticals, Inc. (ADIL)

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer

Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing

ADIL Stock Eyes Best Day In Over 5 Years — Major Pipeline Overhaul And $64M Raise Fuel Rally

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update

Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045

Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program

Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial